Opinion|Videos|August 30, 2024

Overview of Abiraterone and the Differences Between Formulations

Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD

This discussion provides an overview of abiraterone and the key differences between micronized and non-micronized formulations, including considerations for choosing between the two formulations.

Episodes in this series

2 KOLs are featured in this series.

EP. 1 Expert Perspective on the Expanding Treatment Landscape in mCRPC

2 KOLs are featured in this series.

EP. 2 The Role of Androgen Receptor-Targeted Therapy in the Treatment of mCRPC

2 KOLs are featured in this series.

EP. 3 Management of Comment Adverse Effects Associated with mCRPC Therapies

2 KOLs are featured in this series.

EP. 4 Treatment Sequencing With Androgen Receptor-Targeted Therapies for mCRPC

2 KOLs are featured in this series.

EP. 5 Overview of Abiraterone and the Differences Between Formulations

2 KOLs are featured in this series.

EP. 6 Combining Abiraterone with Steroids

2 KOLs are featured in this series.

EP. 7 The Importance of Serum Testosterone Levels With the Use of Androgen Receptor-Targeting Therapies

2 KOLs are featured in this series.

EP. 8 Clinical Attributes of Patients Who Would Benefit From Micronized Abiraterone

2 KOLs are featured in this series.

EP. 9 Dosing and Administration Considerations for Abiraterone Formulations

2 KOLs are featured in this series.

EP. 10 Access Challenges Regarding the Use of Abiraterone in Patients With mCRPC

2 KOLs are featured in this series.

EP. 11 Future Directions in mCRPC

Please provide a brief overview of abiraterone and the key differences between micronized and non-micronized formulations.
How do you approach deciding between the 2 formulations (micronized vs non-micronized)?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Timothy McClure, MD, on 2-year PRESERVE trial results for focal IRE

ByTimothy D. McClure, MD

August 31st 2026

FDA greenlights phase 1 trial of ADI-212 in mCRPC

ByHannah Clarke

August 28th 2026

Initial prostate cancer presentation, family history linked to survival in mCRPC

ByHannah Clarke

August 27th 2026

Metabolic syndrome frequent during first year of ADT-ARPI therapy for prostate cancer

ByHannah Clarke

August 25th 2026

How ARASEC and ARACOG are reshaping mCSPC treatment choices

ByUrology Times staff

August 24th 2026

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA greenlights phase 1 trial of ADI-212 in mCRPC

Mary Dunn, MSN, RN, NP-C, OCN, on the role of APPs in genetic testing

State of Men’s Health Act: What urologists need to know

Defining High-Risk NMIBC and Diagnostic Gaps Before Referral

Initial prostate cancer presentation, family history linked to survival in mCRPC